MedKoo product information:

  X-82

VEGFR/PDGFR dual kinase inhibitor X-82 is an orally available small molecule dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) with antiangiogenic and antineoplastic activities. VEGFR/PDGFR dual kinase inhibitor X-82 inhibits all isoforms of VEGFR and PDGFR, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and PDGFRs are receptor tyrosine kinases that may be upregulated in various tumor cell types. VEGFR/PDGFR dual kinase inhibitor X-82 has been shown to reduce tissue toxicity by 95 percent compared with first-generation kinase inhibitors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

X-82 was designed to reduce the toxicity while maintaining the efficacy of existing VEGFR/PDGFR inhibitors. In December of 2010, Xcovery initiated a First-in-human Phase I clinical trial for X-82 in advanced solid tumors. The trial is being conducted at Sarah Cannon Research Institute under the direction of Dr. Johanna Bendell. (Tyrogenex is a part of the Xcovery Group of companies, founded by Biocatalyst International).

Current developer:    Tyrogenex/Xcovery Group/Biocatalyst International